Patents by Inventor Anastasia Khvorova

Anastasia Khvorova has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS
    Publication number: 20160244765
    Abstract: The present invention relates to RNAi constructs with minimal double-stranded regions, and their use in gene silencing. RNAi constructs associated with the invention include a double stranded region of 8-14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing.
    Type: Application
    Filed: September 25, 2015
    Publication date: August 25, 2016
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
  • METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
    Publication number: 20160201058
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for TTR.
    Type: Application
    Filed: December 10, 2015
    Publication date: July 14, 2016
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • Methods and Compositions for Selecting siRNA of Improved Functionality
    Publication number: 20160201065
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. Be selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods compositions, and kits generated through rational design of siRNAs are disclosed, including those directed to the nucleotide sequences for HAO1.
    Type: Application
    Filed: November 10, 2015
    Publication date: July 14, 2016
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • Methods and Compositions for Selecting siRNA of Improved Functionality
    Publication number: 20160194646
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. Be selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods compositions, and kits generated through rational design of siRNAs are disclosed, including those directed to the nucleotide sequences for F12.
    Type: Application
    Filed: November 9, 2015
    Publication date: July 7, 2016
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • Methods and Compositions for Selecting siRNA of Improved Functionality
    Publication number: 20160193242
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. Be selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods compositions, and kits generated through rational design of siRNAs are disclosed, including those directed to the nucleotide sequences for AAT.
    Type: Application
    Filed: November 9, 2015
    Publication date: July 7, 2016
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • Micro-RNA scaffolds and non-naturally occurring micro-RNAs
    Patent number: 9353368
    Abstract: The present disclosure provides a non-naturally occurring miRNA having a stem-loop structure comprising a scaffold derived from a first endogenous miRNA (e.g., miR-196a-2 or miR-204), a mature strand derived from a second endogenous miRNA, and a star strand sequence that is at least partially complementary to the mature strand sequence. The present disclosure also provides a non-naturally occurring miRNA having a stem-loop structure comprising a scaffold derived from an endogenous miRNA (e.g., miR-196a-2 or miR-204), a mature strand designed t be at least partially complementary to a target RNA, and a star strand sequence that is at least partially complementary to the mature strand sequence. The methods and compositions of the disclosure may be used to mediate gene silencing via the RNAi pathway.
    Type: Grant
    Filed: May 22, 2008
    Date of Patent: May 31, 2016
    Assignee: GE Healthcare Dharmacon, Inc.
    Inventors: Melissa Kelley, Amanda Birmingham, Jon Karpilow, Anastasia Khvorova, Kevin Sullivan
  • RNA interference in dermal and fibrotic indications
    Patent number: 9340786
    Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal and fibrotic applications.
    Type: Grant
    Filed: March 24, 2011
    Date of Patent: May 17, 2016
    Assignee: RXi Pharmaceuticals Corporation
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, Lyn Libertine, James Cardia, Karen G. Bulock
  • REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS
    Publication number: 20160130578
    Abstract: The present invention relates to methods for in vivo administration of sd-rxRNA molecules.
    Type: Application
    Filed: June 2, 2015
    Publication date: May 12, 2016
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
  • Minor groove binder (MGB)-oligonucleotide miRNA antagonists
    Patent number: 9334495
    Abstract: Compositions and methods for inhibiting the actions of non-coding RNAs such as miRNAs and piRNAs are provided. The compositions comprise single or double stranded oligonucleotides conjugated with Minor Groove Binders (“MGBs”). The oligonucleotides can vary in length, can contain nucleotides having one or more modifications, and have regions that are substantially complementary to one or more mature miRNAs or piRNAs.
    Type: Grant
    Filed: November 23, 2010
    Date of Patent: May 10, 2016
    Assignee: ELITECHGROUP B.V.
    Inventors: Anastasia Khvorova, Annaleen Vermeulen, Rob Kaiser, Jon Karpilow, Nicolaas M. J. Vermeulen, Walt Mahoney
  • RNA INTERFERENCE IN OCULAR INDICATIONS
    Publication number: 20160115482
    Abstract: The present invention relates to ocular administration of sd-rxRNA and rxRNAori molecules.
    Type: Application
    Filed: June 2, 2015
    Publication date: April 28, 2016
    Inventors: Lyn Libertine, Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia, Pamela A. Pavco
  • INHIBITION OF MAP4K4 THROUGH RNAI
    Publication number: 20160115484
    Abstract: RNAi constructs directed to MAP4K4 that demonstrate unexpectedly high gene silencing activities, and uses thereof are disclosed. The blunt-ended constructs have a double-stranded region of 19-49 nucleotides. The constructs have selective minimal modifications to confer an optimal balance of biological activity, toxicity, stability, and target gene specificity. For example, the strands may be modified (e.g., one or both ends of the sense strand is modified by 2?-O-methyl groups), such that the construct is not cleaved by Dicer or other RNAse III, the antisense strand may also be modified by a 2?-O-methyl group at the penultimate 5?-end nucleotide to greatly reduce off-target silencing.
    Type: Application
    Filed: June 2, 2015
    Publication date: April 28, 2016
    Inventors: Tod M. Woolf, Joanne Kamens, Anastasia Khvorova, William Salomon
  • RNA interference in skin indications
    Patent number: 9303259
    Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: April 5, 2016
    Assignee: RXi Pharmaceuticals Corporation
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, James Cardia
  • Micro-RNA scaffolds and non-naturally occurring micro-RNAs
    Patent number: 9284554
    Abstract: The present disclosure provides a non-naturally occurring miRNA having a stem-loop structure comprising a scaffold derived from a first endogenous miRNA (e.g., miR-196a-2 or miR-204), a mature strand derived from a second endogenous miRNA, and a star strand sequence that is at least partially complementary to the mature strand sequence. The present disclosure also provides a non-naturally occurring miRNA having a stem-loop structure comprising a scaffold derived from an endogenous miRNA (e.g., miR-196a-2 or miR-204), a mature strand designed to be at least partially complementary to a target RNA, and a star strand sequence that is at least partially complementary to the mature strand sequence. The methods and compositions of the disclosure may be used to mediate gene silencing via the RNAi pathway.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: March 15, 2016
    Assignee: GE Healthcare Dharmacon, Inc.
    Inventors: Melissa Kelley, Amanda Birmingham, Jon Karpilow, Anastasia Khvorova, Kevin Sullivan
  • Methods and compositions for selecting siRNA of improved functionality
    Patent number: 9228186
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for TTR.
    Type: Grant
    Filed: December 5, 2013
    Date of Patent: January 5, 2016
    Assignee: Thermo Fisher Scientific Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • Reduced size self-delivering RNAi compounds
    Patent number: 9175289
    Abstract: The present invention relates to RNAi constructs with minimal double-stranded regions, and their use in gene silencing. RNAi constructs associated with the invention include a double stranded region of 8-14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing.
    Type: Grant
    Filed: May 15, 2014
    Date of Patent: November 3, 2015
    Assignee: RXi Pharmaceuticals Corporation
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
  • RNA interference in ocular indications
    Patent number: 9095504
    Abstract: The present invention relates to ocular administration of sd-rxRNA and rxRNAori molecules.
    Type: Grant
    Filed: March 24, 2011
    Date of Patent: August 4, 2015
    Inventors: Lyn Libertine, Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
  • Reduced size self-delivering RNAi compounds
    Patent number: 9080171
    Abstract: The present invention relates to methods for in vivo administration of sd-rxRNA molecules.
    Type: Grant
    Filed: March 24, 2011
    Date of Patent: July 14, 2015
    Assignee: RXi Parmaceuticals Corporation
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
  • Inhibition of MAP4K4 through RNAI
    Patent number: 9074211
    Abstract: RNAi constructs directed to MAP4K4 that demonstrate unexpectedly high gene silencing activities, and uses thereof are disclosed. The blunt-ended constructs have a double-stranded region of 19-49 nucleotides. The constructs have selective minimal modifications to confer an optimal balance of biological activity, toxicity, stability, and target gene specificity. For example, the strands may be modified (e.g., one or both ends of the sense strand is modified by 2?-O-methyl groups), such that the construct is not cleaved by Dicer or other RNAse III, the antisense strand may also be modified by a 2?-O-methyl group at the penultimate 5?-end nucleotide to greatly reduce off-target silencing.
    Type: Grant
    Filed: November 19, 2009
    Date of Patent: July 7, 2015
    Assignee: RXi Pharmaceuticals Corporation
    Inventors: Tod M. Woolf, Joanne Kamens, Anastasia Khvorova, William Salomon
  • Minor groove binder (MGB)-oligonucleotide miRNA antagonists
    Patent number: 8980855
    Abstract: Compositions and methods for inhibiting the actions of non-coding RNAs such as miRNAs and piRNAs are provided. The compositions comprise single or double stranded oligonucleotides conjugated with Minor Groove Binders (“MGBs”). The oligonucleotides can vary in length, can contain nucleotides having one or more modifications, and have regions that are substantially complementary to one or more mature miRNAs or piRNAs.
    Type: Grant
    Filed: June 7, 2012
    Date of Patent: March 17, 2015
    Assignees: Elitech Holding B.V., GE Healthcare Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Annaleen Vermeulen, Rob Kaiser, Jon Karpilow, Nicolaas M. J. Vermeulen, Walt Mahoney
  • siRNA targeting catenin, beta-1 (CTNNB1)
    Patent number: 8937172
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for CTNNB1.
    Type: Grant
    Filed: February 12, 2013
    Date of Patent: January 20, 2015
    Assignee: Thermo Fisher Scientific Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe